# Fibroblast Activity (PRO-C3) and Liver Stiffness Correlate with spatial distribution of Collagens in MASLD and ALD: Insights from Digital Pathology

<sup>1</sup>Nordic Bioscience A/S, Biomarkers & Research, Herlev, Denmark, <sup>2</sup>Centre for Liver Research, Department of Clinical Research, Intersity Hospital, Odense, Denmark, <sup>3</sup>Department of Clinical Research, Intersity Hospital, Odense, Department of Clinical Research, Intersity Hospital, Odense, Department of Clinical Research, Intersity Hospital, Odense, Department, Intersity Hospital, Intersity, Inte Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark, Odense Mainz, Germany, <sup>6</sup>Histoindex Pte Itd, Singapore, <sup>7</sup>Department of Pathology, University Medical Center Mainz, Germany

# BACKGROUND

In patients with metabolic dysfunction associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD) Kleiner fibrosis stage provides limited information on the spatial distribution of collagen in the liver. Digital pathology provides a more advanced assessment of collagen localization; however, there is limited knowledge linking non-invasive tests to the spatial distribution of collagen.

Our aim was to explore the ability of digital pathology by second harmonic generation to evaluate fibrosis in ALD and MASDL as well as investigate the correlation between the spatial distribution of collagens and fibroblast activity (PRO-C3)

# METHODS

- Liver biopsies and serum samples from 121 patients with MASLD enrolled at the University Medical Center Mainz, and 31 patients with ALD from the GALA-POSTBIO phase 2 trial conducted at the Centre for Liver Research, Odense University Hospital were evaluated.
- Second harmonic imaging (SHG) by Histoindex was used to quantitate hepatic fibrosis by qFibrosis (qFib) on unstained liver biopsies. qFib is a composite index combining collagen-related morphological parameters across different regions in the liver lobule.
- NordicPRO-C3<sup>™</sup>, a blood-based type III collagen formation marker of fibroblast activity was measured by ELISA and the ADAPT algorithm was calculated (PRO-C3, age, diabetes Y/N, platelets) and both correlated to the SHG analysis.
- Transient elastography (TE) was assessed by Fibroscan and correlated to the SHG analysis together with ALT and AST.

### RESULTS

- Baseline demographics are seen in table 1 (MASLD cohort) and table 2 (ALD cohort).
- The Spearman correlation between PRO-C3 and qFib was similar in MASLD: (r=0.56, p>0.0001) and in ALD (r=0.55, p=0.001) (Fig 1 & 4)
- The ADAPT score (PRO-C3, diabetes, platelets, age) was highly correlated to qFib in MASLD (r=0.72, p>0.0001) and less in ALD (r=0.43, p=0.018). TE was correlated to qFib in MASLD (r=0.58, p>0.0001) and in ALD (0.46, p=0.010).
- The absolute amount of collagen across all regions (%SHG) correlated to PRO-C3 in MASLD (r=0.33, p=0.0002), and in ALD (r=0.54, p=0.002); ADAPT in MASLD (r=0.39, p= p>0.0001) and ALD (r=0.39, 0.032) as well as TE in MASLD (r=0.38, p<0.001) and ALD (r=0.51, p<0.004).
- No correlation between qFib or %SHG were seen for AST or ALT in MASLD and ALT in ALD, except for AST versus qFib (r=0.41, p=0.028) and AST versus %SHG (r=0.42, p=0.024) in ALD only.
- Finally, the spatial distribution of collagen correlated with PRO-C3, ADAPT, TE for portal tract (StrAreaPT, StrArea; StrLengthPT) however not to AST or ALT.



Acknowledgement: Boehringer Ingelheim cosponsored the current study

Diana Julie Leeming<sup>1</sup>, Johanne Kragh Hansen<sup>2,3</sup>, Jörn M Schattenberg<sup>4</sup>, Peder Frederiksen<sup>1</sup>, Andressa de Zawadzki<sup>1</sup>, Maurice Michel<sup>4</sup>, Christian Labenz<sup>5</sup>, Yayun Ren<sup>6</sup>, Elaine Chng<sup>6</sup>, Beate Straub<sup>7</sup>, Maja Thiele<sup>2,3</sup>, Morten Karsdal<sup>1</sup>, Yukti Choudhury<sup>6</sup>, Aleksander Krag<sup>2,3</sup>, Dean Tai<sup>6</sup>


# **RESULTS-MASLD (F0-F4)**

mograp	hics n=	121	
,			qFibrosis Value
	Median (Q1, Q3)	n (%)	
Age (Years)	54.0 (44.0, 60.0)		
BMI (kg/m <sup>2</sup> )	32.4 (29.4, 36.4)		
AST (U/L)	49.0 (38.0, 67.0)		
ALT (U/L)	73.0 (50.0, 109.0)		
FIB4	1.3 (0.9, 1.8)		
PRO-C3 (ng/mL)	11.5 (9.4, 16.6)		
ADAPT	5.4 (4.3, 6.8)		
<u>TE(</u> kPa)	8.2 (5.6, 12.6)		
gFibrosis value	1.7 (1.4, 2.4)		
Sex (male)		66 (54.5%)	
Diabetes (no)		73 (60.8%)	
Fibrosis stage		F0 (n=4, 3.3%); Fl	
		(n=34, 28.1%); F2	
		(n=46, 38.0%);	
		F3 (n=25, 20.7%);	
		F4 (n=12, 9.9%)	
<u>qFibrosis</u> stage		0 (n=11, 9.1%); 1	
		(n=25, 20.7%); 2	
		(n=44, 36.4%); 3	
		(n=29, 24.0%); 4 (n=12, 9.9%)	Figu

# **RESULTS – GALA-POSTBIO; ALD (F2-4)**

Demographics n=31	
Table 2.	


	Median (Q1, Q3)	(n, %)
Age (Years)	64.0 (59.5, 68.5)	
BMI (kg/m²)	29.6 (24.6, 33.6)	
AST (U/L)	42.0 (34.0, 64.0)	
ALT (U/L)	33.0 (23.5, 57.5)	
FIB4	3.0 (1.8, 4.7)	
PRO-C3 (ng/mL)	22.6 (19.2, 28.3)	
ADAPT	8.1 (7.2, 9.0)	
TE (kPa)	21.1 (14.4, 32.0)	
gFibrosis value	3.4 (2.4, 5.0)	
Sex (male)		26 (83.9%)
Diabetes (no)		25 (80.6%)
Fibrosis stage		F2 (n=1, 13.2%);
		F3 (n=11,
		35.5%); F4
		(n=19, 61.3%)
<u>qFibrosis</u> stage		1 (n=2, 6.5%); 2
		(n=5, 16.1%); 3
		(n=9, 29.0%); 4
		(n=15, 48.4)



patients (n=31)

# Key Messages

- liver stiffness in both MASLD and ALD.
- size.
- for liver fibrosis.



eatmap of Spearman's rank correlations in MASLD





Figure 2. Scatter plots between A) PRO-C3 (ELISA), B) ADAPT, C) TE, or D) ALT and gFibrosis in MASLD patients



**Figure 5.** Scatter plots between A) PRO-C3 (ELISA), B) ADAPT, C) TE, or D) ALT and qFibrosis in ALD patients

• We observed correlations between spatial distribution of collagens and systemically assessed active fibrogenesis and • While similarities and differences were observed, these correlations were potentially influenced by etiology and sample • These findings underscore the connection between biopsy-based digital pathology assessments and non-invasive tests

**SEASL** CONGRESS 7-10 May 2025

Amsterdam, the Netherlands






Figure 3. Plots of A) PRO-C3 (ELISA), B) ADAPT, C) TE, or D) ALT levels at gFibrosis stage 0-4.

#### Histoindex analysis








Figure 6. Digital images showing A) Masson Trichrome-stain B)SHG-scan and C) qFibrosis detection of PT: Portal Tract, CV: Central Vein. Evaluation of collagen parameters on (D) SHG/Two-photon Excitation Fluorescence (TPEF) image; (E) high magnification imaging of area denoted within the blue square in Figure 6D; (F) AI identification of string length (StrLength), string area (StrArea), string width (StrWidth)

> The FIB-NIT Par Part of the Nordi ProteinFingerPrint Technology™



Scan to

Poster Ading KNOWLEDGE





